Anna Berkenblit, Chief Scientific and Medical Officer at Pancreatic Cancer Action Network, Board Member at TORL Biotherapeutics LLC, shared on LinkedIn:
“Now that we’re on the brink of KRAS-targeting therapies for treating pancreatic cancer, there’s also encouraging early data from Johns Hopkins Kimmel Cancer Center on a mutant KRAS vaccine designed to help prevent pancreatic cancer in people at elevated risk due to pancreatic cysts.”
Title: First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts
Authors: S. Daniel Haldar, Amanda L. Huff, Hejia Henry Wang, Zirui Zhu, Maureen Berg, Jiayun Lu, Nancy Sun, Elizabeth Abou Diwan, Hassan Sinan, Christopher J. Thoburn, Matthew Z. Guo, Takeichi Yoshida, Linda C. Chu, Anna K. Ferguson, Dimitrios N. Sidiropoulos, Luciane T. Kagohara, Won Jin Ho, Katherine M. Bever, Marina Baretti, Mark Yarchoan, Daniel A. Laheru, Julie M. Nauroth, Amy M. Thomas, Hao Wang, Nilofer Saba Azad, Michael G. Goggins, Elizabeth M. Jaffee, Neeha Zaidi.
Other articles about GI Oncology on OncoDaily.